secwatch / observer
8-K filed March 1, 2023, 6:59 PM ET CIK 0001603207
regulatory confidence high sentiment neutral materiality 0.60

Notable Labs, Ltd.: Nasdaq/NYSE listing notice — Vascular Biogenics transfers listing to Nasdaq Capital Market; gets 180-day extension to meet bid price rule

Notable Labs, Ltd.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Notable Labs, Ltd. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(ii)).

Exchange
nasdaq
Notice
extension granted
Deficiency
minimum bid price
Rules
5450(a)(1), 5810(c)(3)(A)(ii)
Exact text from the filing
February 28, 2023, VBL received confirmation that Nasdaq had approved the Transfer, and VBL’s ordinary shares will begin trading on The Nasdaq Capital Market effective with the open of trading on March 2, 2023. VBL’s ordinary shares continue to trade under the symbol “VBLT”. The Nasdaq Capital Market operates in substantially the same manner as The Nasdaq Global Market, with issuers listed on The Nasdaq Capital Market tier required to meet certain financial and corporate governance requirements to qualify for continued listing. On February 28, 2023, VBL received confirmation that Nasdaq has de
View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR
accession 0001493152-23-006353
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.